Cargando…
The Proliferation REduction with Vascular ENergy Trial (PREVENT)
PREVENT was the first prospective, randomized placebo-controlled study of intracoronary beta radiotherapy with (32)P. A total of 105 patients with de novo or restenotic lesions, treated by stenting or balloon angioplasty, received 0 (control), 16, 20, or 24 Gy to a depth of 1 mm beyond the lumen sur...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59647/ https://www.ncbi.nlm.nih.gov/pubmed/11806768 http://dx.doi.org/10.1186/cvm-2-1-016 |
_version_ | 1782120093414588416 |
---|---|
author | Raizner, Albert E Kaluza, Grzegorz L |
author_facet | Raizner, Albert E Kaluza, Grzegorz L |
author_sort | Raizner, Albert E |
collection | PubMed |
description | PREVENT was the first prospective, randomized placebo-controlled study of intracoronary beta radiotherapy with (32)P. A total of 105 patients with de novo or restenotic lesions, treated by stenting or balloon angioplasty, received 0 (control), 16, 20, or 24 Gy to a depth of 1 mm beyond the lumen surface. Rates of restenosis (50% diameter stenosis or more) were significantly lower in radiotherapy patients at the target site (8% compared with 39%, P = 0.012) and at the target site plus adjacent segments (22% compared with 50%, P = 0.018). Stenosis adjacent to the target site and late thrombotic events reduced the overall clinical benefit of radiotherapy. |
format | Text |
id | pubmed-59647 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2001 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-596472001-11-06 The Proliferation REduction with Vascular ENergy Trial (PREVENT) Raizner, Albert E Kaluza, Grzegorz L Curr Control Trials Cardiovasc Med Commentary PREVENT was the first prospective, randomized placebo-controlled study of intracoronary beta radiotherapy with (32)P. A total of 105 patients with de novo or restenotic lesions, treated by stenting or balloon angioplasty, received 0 (control), 16, 20, or 24 Gy to a depth of 1 mm beyond the lumen surface. Rates of restenosis (50% diameter stenosis or more) were significantly lower in radiotherapy patients at the target site (8% compared with 39%, P = 0.012) and at the target site plus adjacent segments (22% compared with 50%, P = 0.018). Stenosis adjacent to the target site and late thrombotic events reduced the overall clinical benefit of radiotherapy. BioMed Central 2001 2001-02-01 /pmc/articles/PMC59647/ /pubmed/11806768 http://dx.doi.org/10.1186/cvm-2-1-016 Text en Copyright © 2001 Raizner and Kaluza; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any purpose, provided this notice is preserved along with the article's original URL. |
spellingShingle | Commentary Raizner, Albert E Kaluza, Grzegorz L The Proliferation REduction with Vascular ENergy Trial (PREVENT) |
title | The Proliferation REduction with Vascular ENergy Trial (PREVENT) |
title_full | The Proliferation REduction with Vascular ENergy Trial (PREVENT) |
title_fullStr | The Proliferation REduction with Vascular ENergy Trial (PREVENT) |
title_full_unstemmed | The Proliferation REduction with Vascular ENergy Trial (PREVENT) |
title_short | The Proliferation REduction with Vascular ENergy Trial (PREVENT) |
title_sort | proliferation reduction with vascular energy trial (prevent) |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59647/ https://www.ncbi.nlm.nih.gov/pubmed/11806768 http://dx.doi.org/10.1186/cvm-2-1-016 |
work_keys_str_mv | AT raizneralberte theproliferationreductionwithvascularenergytrialprevent AT kaluzagrzegorzl theproliferationreductionwithvascularenergytrialprevent AT raizneralberte proliferationreductionwithvascularenergytrialprevent AT kaluzagrzegorzl proliferationreductionwithvascularenergytrialprevent |